Taken together, these findings indicate that MEK/Bcl‐2 inhibition shows selectivity for CLL cells, and that early induction of apoptosis can predict sensitivity in 72‐h assays. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.